– USA, MA – Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced the appointment of clinical oncology expert, David Parkinson, M.D., to its Board of Directors, effective as of October 29, 2014. With Dr. Parkinson’s appointment, Cerulean has formed a Clinical Advisory Committee of the Board, which will consist of Dr. Parkinson, Dr. Susan Kelley and Dr. Paul Friedman.
“Dr. Parkinson has outstanding experience in all aspects of oncology research and development, including leadership roles at large pharmaceutical and biotechnology companies, as well as oversight of a major branch of the National Cancer Institute. We are therefore very pleased to welcome him to the Cerulean team,” said Dr. Friedman, who will assume the role of Executive Chairman of Cerulean effective October 29, 2014. “Dr. Parkinson’s appointment comes at an opportune time as Cerulean approaches several clinical development milestones for our lead candidate, CRLX101.”
“Cerulean’s nanoparticle-drug conjugates, or NDCs, have the ability to selectively target tumor cells with potent anti-cancer payloads, which could drive activity and significantly reduce toxicities seen with traditional cancer drugs,” commented Dr. Parkinson. “I look forward to contributing to the clinical trial strategy to bring these compounds to patients in need.”
Dr. Parkinson is a venture partner at New Enterprise Associates (NEA). Previously, Dr. Parkinson served as President and CEO of Nodality, a company focused on the biological characterization of signaling pathways in patients with malignancies to enable more effective therapeutics development and clinical decision-making. Prior to that, Dr. Parkinson was senior vice president of Oncology Research and Development at Biogen Idec, vice president of Oncology Development at Amgen and vice president of Global Clinical Oncology Development at Novartis. Dr. Parkinson also worked at the National Cancer Institute, serving as chief of the Investigational Drug Branch, then as acting associate director of the Cancer Therapy Evaluation Program.
Dr. Parkinson held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. Dr. Parkinson received his M.D. as gold medalist from the University of Toronto Faculty of Medicine, with Internal Medicine and Hematology/Oncology training at McGill University and at the New England Medical Center.
Dr. Parkinson is a past chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He is a past president of the International Society of Biological Therapy, and past editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine. He has recently completed a term on the FDA’s Science Board as well as a term on the Board of Directors of the American Association of Cancer Research (AACR). He continues to serve as Chairman of the AACR Finance Committee.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
